Brokerages Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Price Target at $52.33

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have been given an average rating of “Moderate Buy” by the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $52.3333.

A number of equities research analysts have commented on KNSA shares. TD Cowen began coverage on Kiniksa Pharmaceuticals International in a report on Monday, September 29th. They set a “buy” rating and a $60.00 price target on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Zacks Research cut Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. The Goldman Sachs Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd.

Kiniksa Pharmaceuticals International Trading Up 1.5%

NASDAQ KNSA opened at $42.44 on Friday. Kiniksa Pharmaceuticals International has a 12 month low of $18.12 and a 12 month high of $44.42. The stock has a market cap of $3.22 billion, a price-to-earnings ratio of 94.31 and a beta of 0.04. The company’s 50 day moving average is $41.42 and its two-hundred day moving average is $37.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm had revenue of $180.86 million during the quarter, compared to analysts’ expectations of $166.64 million. During the same period last year, the company earned ($0.18) earnings per share. The business’s revenue for the quarter was up 61.2% on a year-over-year basis. Sell-side analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CFO Mark Ragosa sold 12,000 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $41.89, for a total transaction of $502,680.00. Following the completion of the transaction, the chief financial officer owned 19,086 shares of the company’s stock, valued at $799,512.54. This represents a 38.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Eben Tessari sold 12,048 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the completion of the sale, the chief operating officer directly owned 16,666 shares in the company, valued at $692,638.96. This trade represents a 41.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 202,230 shares of company stock worth $8,023,679 in the last quarter. 53.48% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Aberdeen Group plc increased its position in Kiniksa Pharmaceuticals International by 152.4% in the fourth quarter. Aberdeen Group plc now owns 400,598 shares of the company’s stock worth $16,525,000 after purchasing an additional 241,876 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 288.6% in the 4th quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock worth $22,333,000 after buying an additional 402,078 shares in the last quarter. Sound View Wealth Advisors Group LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 16.2% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 14,792 shares of the company’s stock worth $610,000 after buying an additional 2,063 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 4.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock worth $701,000 after buying an additional 771 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Kiniksa Pharmaceuticals International by 42.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,456 shares of the company’s stock valued at $7,473,000 after buying an additional 57,174 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.